App-Quantinova.ai

Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.

Arun Azad - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Phase II study of the efficacy of abirateron acetate with dutasteride for castration-resistant prostate cancer.

Hideyasu Matsuyama - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

18F-fluciclovine positron emission tomography (PET) in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate.

Pedro C. Barata - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.

Christian Gratzke - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Dhruv Bansal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy.

Petros Grivas - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Docetaxel

68Ga-PSMA expression changes on PET/CT for response assessment during taxane-based chemotherapy in metastatic prostate cancer patients.

Qaid Shagera - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in metastatic castration-resistant prostate cancer.

Gunhild Von Amsberg - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Real-world utilization of docetaxel among men with de novo metastatic castration-sensitive prostate cancer: A population-based study in men aged 66 or older.

Bobby Shayegan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Preliminary results from a phase II trial of docetaxel before castration with degarelix in men with newly diagnosed metastatic prostate cancer.

Theodore Stewart Gourdin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).

Tie Zhou - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

18F-DCFPyL PSMA PET imaging compared to conventional imaging in the detection of pelvic nodal metastases in patients with locally advanced or oligometastatic prostate cancer.

Ashanda Rosetta Patrice Esdaille - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.

Daniel M. Geynisman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.

Ashanda Rosetta Patrice Esdaille - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Sequence decision making for cabazitaxel (Cbz) versus abiraterone (Abt) or enzalutamide (Enz) post-docetaxel (Dtx) in a publicly funded health care system.

Alexander Watson - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer.

Mary Mahler - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).

Susan Halabi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

A phase II study to evaluate the effects of docetaxel plus lycopene in advanced castrate-resistant prostate cancer.

Eric Zhuang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial.

Brendan James Connell - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

Docetaxel

Filters

2459 Abstracts